Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of KDR. The page also collects GeneMedi's different modalities and formats products for KDR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the KDR target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]

Target IDGM-T80975
Target NameKDR
Gene ID3791
Gene Official NameKDR
Gene AliasCD309, FLK1, VEGFR, VEGFR2
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target


Pre-made KDR-specific INN-index biosimilar (antibody&conjugates)-Vulinacimab, Olinvacimab, Ramucirumab, Pulocimab, alacizumab pegol, pegdinetanib, Alacizumab, Tanibirumab

Anti-KDR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-632Pre-Made Vulinacimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibodyVulinacimabVEGFR2/KDRWhole mAbINN mab
GMP-Bios-ab-396Pre-Made Olinvacimab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibodyOlinvacimabTanibirumabKDRWhole mAbINN mab
GMP-Bios-ab-468Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibodyRamucirumabKDRWhole mAbINN mab
GMP-Bios-ab-687Pre-Made Pulocimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibodyPulocimabVEGFR2/KDRWhole mAbINN mab
GMP-Bios-INN-723alacizumab pegolKDRpegylatedINN mab
GMP-Bios-INN-950pegdinetanibKDRpegylatedINN mab
GMP-Bios-ab-014Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibodyAlacizumabKDRdi-FabINN mab
GMP-Bios-ab-550Pre-Made Tanibirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibodyTanibirumabolinvacimabKDRWhole mAbINN mab



Pre-made anti-KDR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-KDR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-KDR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T80975-AbAnti-KDR monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibody, Cytokine antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×